Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Corcept Therapeutics (CORT)

Corcept Therapeutics (CORT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
CORT
CORT Q1 Deep Dive: Early Lifyorli Launch and Endocrinology Momentum Offset Margin Pressures StockStory - Mon May 4, 9:10AM CDT

CORT Q1 Deep Dive: Early Lifyorli Launch and Endocrinology Momentum Offset Margin Pressures

CORT : 52.72 (+2.71%)
CORT
Corcept (NASDAQ:CORT) Misses Q1 CY2026 Revenue Estimates StockStory - Thu Apr 30, 4:24PM CDT

Corcept (NASDAQ:CORT) Misses Q1 CY2026 Revenue Estimates

CORT : 52.72 (+2.71%)
Corcept: Q1 Earnings Snapshot AP - Thu Apr 30, 4:23PM CDT

Corcept: Q1 Earnings Snapshot

CORT : 52.72 (+2.71%)
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update Business Wire - Thu Apr 30, 3:05PM CDT

Revenue of $164.9 million, compared to $157.2 million in first quarter 2025 Increase in 2026 revenue guidance to $950 – $1,050 million ...

CORT : 52.72 (+2.71%)
Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis Business Wire - Thu Apr 30, 3:05PM CDT

87 percent reduction in risk of death compared to patients who received placebo (hazard ratio: 0.13, p-value: < 0.0001)

CORT : 52.72 (+2.71%)
Corcept's Revenue Growth Trajectory Gets Its First Test Since Competitor Setbacks Barchart - Wed Apr 29, 4:07PM CDT

Barchart Research What to Expect from CORT Earnings CORT Generated April 29, 2026 Current Price $46.59 EPS Estimate $$-0.30 Consensus Rating Moderate Buy Average Move 3.95% Corcept's Revenue Growth Trajectory...

CORT : 52.72 (+2.71%)
CORT
Corcept Earnings: What To Look For From CORT StockStory - Tue Apr 28, 10:13PM CDT

Corcept Earnings: What To Look For From CORT

CORT : 52.72 (+2.71%)
Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call Business Wire - Thu Apr 23, 3:05PM CDT

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on April 30, 2026. The company will also host a conference...

CORT : 52.72 (+2.71%)
Corcept Deadline Today: CORT Investors with Losses in Excess of $100K Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit PR Newswire - Tue Apr 21, 2:02PM CDT

NEW YORK , April 21, 2026 /PRNewswire/ --

CORT : 52.72 (+2.71%)
Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026 Business Wire - Tue Apr 21, 12:09PM CDT

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic...

CORT : 52.72 (+2.71%)

Barchart Exclusives

After an Earnings Blowout, Morgan Stanley Just Raised This Chip Stock’s Target Price by $8 Barchart - 14 minutes ago
Navitas Semiconductor has a number of strong, positive, potential catalysts, but it's also facing tough competitive threats along with its high price tag. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.